1. Introduction {#sec1}
===============

Few drugs with very different chemical structure, but with the shared characteristic of high lipophilicity, can enter the cells by simple diffusion across the lipid bilayer of the plasma membrane. This is not, however, the common rule. Owing to the fact that the majority of drugs are polar compounds, the participation in their uptake of plasma membrane transporters, belonging to the solute carrier (SLC) superfamily, is required. This includes approximately 300 genes classified into 43 families \[[@B1]\]. Owing to the large variety of carriers involved in transport processes, either by facilitated diffusion or by secondary active symport or antiport concentrative mechanisms, and to their marked overlap in substrate specificity, at the plasma membrane of hepatocytes there is a gate for the uptake of almost every drug \[[@B2]\]. The presence in the liver cells of the required transporter, mainly at the basolateral or sinusoidal membrane of hepatocytes ([Figure 1](#fig1){ref-type="fig"}), and its level of expression under pathological circumstances, when the drug is needed, determine the bioavailability and hence the efficacy of the pharmacological agent.

Regarding the overall detoxification process, and when the desired therapeutic action must take place in the liver itself, the ability to take up the drug and the function of export pumps accounting for the active efflux toward the bile or back to blood are similarly important. These pumps are primary active transporters able to use metabolic energy in the form of ATP to carry out the export of a large variety of substrates across the basolateral and the apical or canalicular plasma membrane of hepatocytes and cholangiocytes. Most of these transporters, but not all, belong to the superfamily of ATP-binding cassette (ABC) proteins that in humans includes 48 genes classified into 7 different families (from ABCA to ABCG). Under physiological circumstances many of them play an important role in barrier mechanisms and secretory functions. Thus, in hepatocytes ABC proteins located at the canalicular membrane are involved in bile formation ([Figure 2](#fig2){ref-type="fig"}). Accordingly, impairment in the expression or function of these pumps accounts for several forms of inherited or acquired intrahepatic cholestasis \[[@B3]\].

Both uptake and efflux transporters expressed in small intestine, liver, and kidney, either in healthy tissues or in tumours, are involved in the mechanisms that determine the pharmacological efficacy of many drugs, including antitumour agents. Thus, a reduction in the uptake of cytostatic drugs has been included among the mechanisms of chemoresistance type 1a (MOC-1a) \[[@B4]\]. Changes in the expression of uptake transporters or the existence of genetic variants \[[@B5]\], as well as the simultaneous administration of inhibitors, may greatly affect (i) the appearance of adverse reactions due to drug-induced toxicity; (ii) the ability of the body to carry out the absorption or excretion of a certain drug; (iii) the efficacy of this drug to reach sufficient intracellular concentrations in the target cells \[[@B6]\]. At this respect, a question of great impact and increasing interest is the possibility that coadministration of certain drugs with food containing substrates or inhibitors of the involved transporter may affect the overall pharmacokinetics of these drugs. However, our knowledge of the potential risk of nutrient-drug interactions is still limited \[[@B7]\].

The net transport function is also determined by the existence of mechanisms of internalization of carrier proteins from the plasma membrane. Interestingly, this process can be pharmacologically manipulated. A good example is the effect of 4-phenylbutyrate, a drug used to treat ornithine transcarbamylase deficiency, on the amount of the bile salt export pump (BSEP, gene symbol *ABCB11*) protein inserted at the canalicular membrane of hepatocytes. Treatment with 4-phenylbutyrate induces downregulation of subunits (*α*- and *μ*2-adaptin) of the AP2 adaptor complex. This mediates clathrin-dependent endocytosis and subsequent degradation of BSEP \[[@B8]\].

2. Drug Uptake Transporters {#sec2}
===========================

In addition to changes in the expression levels due to exogenous or endogenous factors that may be influenced by different stimuli, such as seasonal, endocrine, nutritional, and exposure to xenobiotics, the existence of polymorphisms in genes of SLC superfamily expressed in liver cells accounts for a marked interindividual sensitivity to many drugs whose activity is performed on liver cells or whose metabolism and/or elimination depends on the hepatic function \[[@B9]\]. Moreover, it should be taken into account that, although we will focus this paper on liver processes, the availability of the drugs reaching the liver could be greatly modified by similar transporters involved in their intestinal absorption and renal elimination.

2.1. OATP Family {#sec2.1}
----------------

An important role in drug uptake by the liver is played by members of the superfamily of organic anion transporting polypeptides (OATP) encoded by *SLCO* (previously known as *SLC21*) genes \[[@B10]\]. The 11 human isoforms of OATPs are classified into 6 families (from OATP1 to OATP6) on the basis of their amino acid sequence similarities (\>40%), and several subfamilies (1A, 1B, etc.) with members sharing higher (\>60%) amino acid identity. These proteins have the common characteristic of containing 12 transmembrane domains with both amino and carboxyl termini intracellularly oriented. Three major OATP isoforms are expressed at the basolateral membrane of hepatocytes: OATP1B1 (previously known as OATP-C, gene symbol *SLCO1B1*), OATP1B3 (previously known as OATP8, gene symbol *SLCO1B3*), and OATP2B1 (previously known as OATP-B, gene symbol *SLCO2B1*). However, other members of this family are also expressed in liver (OATP3A1 \> OATP1A2 \> OATP1C1 \> OATP2A1 *≈* OATP4A1) \[[@B11]\]. Neutral anion exchange has been proposed as the general mechanism for most members of this family of transporters, being bicarbonate the exchanged anion \[[@B12]\]. However, recent results indicate that at least the two OATP isoforms primarily expressed in the liver, namely, OATP1B1 and OATP1B3, are electrogenic transporters, although their activity may be strongly affected under circumstances of abnormal variations of local pH \[[@B13]\]. This is pharmacologically important because tumour environment is often acidic and both transporters can be the gate for the entrance in liver tumours of many cytostatic drugs \[[@B14]\], such as irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38) \[[@B15]\], flavopiridol \[[@B16]\], methotrexate \[[@B17]\], paclitaxel \[[@B18]\], and several bile acid-cisplatin conjugates (BAMET) \[[@B19]\]. OATP2B1 is expressed in territories other than liver, where this transporter is involved in the uptake of different drugs. Thus, OATP2B1 has been recently identified as a carrier for the antiarrhythmic agent amiodarone \[[@B20]\] and antifolate drugs \[[@B21]\]. Another member of this family, OATP1A2 (previously known as OATP-A, gene symbol *SLCO1A2*), is also expressed, although at low level, in the liver. This transporter is pharmacologically interesting due to its presence in cholangiocytes \[[@B22]\] and because its ability to transport antitumour drugs, such as methotrexate \[[@B23]\] and imatinib \[[@B24]\]. A complete list of substrates for OATP1B1, OATP1B3, and OATP1A2 is shown in [Table 1](#tab1){ref-type="table"}.

Clinically important drug interactions leading to adverse drug reactions have been traditionally associated with impaired metabolic detoxification (phase I and phase II processes) of the administered drug. However, at present the accepted concept includes that some drug interactions result from changes in the activity and/or expression of drug transporters \[[@B25]\]. Owing to the promiscuity of OATP isoforms, there are many examples of drug-drug, endogenous compounds-drug and food components-drug interactions involving these transporters. Thus OATP1A2-mediated uptake of the histamine H1-receptor antagonist fexofenadine, used for the temporary relief of runny nose, sneezing, and nasal stuffiness from common cold, is inhibited by several drugs, including antivirals, antifungals and anticholesterol drugs \[[@B26]\], and flavonoids contained in grapefruit, such as naringin \[[@B27]\]. The ability of grapefruit and orange juices to interfere with OATP-mediated drug uptake has been also suggested for OATP2B1 \[[@B28]\]. Several important drug interactions with clinical relevance have been described for OATP1B1 and OATP1B3, such as cerivastatin-gemfibrozil \[[@B29], [@B30]\] and atorvastatin-rifampin \[[@B31]\].

The importance of OATPs in the liver handling of many drugs accounts for the fact that environmental and genetic factors able to perturb their expression and activity can contribute to adverse drug reactions (ADR) \[[@B32]\]. This may occur due to single nucleotide polymorphisms (SNPs) that change OATP activity and to epigenetic regulation that modify OATP expression levels, and sometimes these changes accompany certain liver diseases. In patients with primary biliary cirrhosis, haemochromatosis and nonalcoholic steatohepatitis with altered hepatic expression of vitamin C transporters SLC23A1 and SLC23A2, the mRNA levels of OATP1A2, OATP1B1, and OATP1B3 were not changed \[[@B33]\]. In contrast, decreased expression of OATP1B1 has been found as a shared characteristic of hepatocellular carcinoma, and cholangiocarcinoma \[[@B34]\].

Regarding the effect of genetic variants two examples can illustrate the clinical importance of identifying patients carrying polymorphisms that can affect OATP function. This is the case of some SNPs, such as c.521T \> C (p.Val174Ala) in *SLCO1B1*, which results in impaired OATP1B1 function \[[@B35]\]. This may account for either adverse or protective effects, as will be commented below. Patients with this SNP show more than 3-fold increased serum concentrations of simvastatin acid, the active metabolite of simvastatin, when receiving this drug \[[@B36]\]. This has been associated with a higher risk of suffering from myopathy when these patients are treated with a high dose of simvastatin (80 mg/day) for some time \[[@B37]\]. In contrast, they are partly protected against the adverse effects of mycophenolic acid \[[@B38]\]. This is the active moiety of mycophenolate mofetil, a drug used as immunosuppressant in patients undergoing kidney transplantation. Unfortunately ADR, characterized by nausea, vomiting, hematotoxicity, and infections, affects up to 50% of treated patients. Interestingly, mycophenolic acid is not a substrate of OATP1B1, whereas its glucuronate derivatives are taken up by hepatocytes through this carrier \[[@B39]\]. Thus, mycophenolic acid is biotransformed by hepatocytes to glucuronides that are secreted into bile through the canalicular multidrug resistance-associated protein (MRP2, gene symbol *ABCC2*). The reabsorbed metabolites are maintained in the enterohepatic circulation due in part to OATP1B1 activity. This recycling is impaired in carriers of *SLCO1B1*-c.521C variant in whom reduced hepatocellular uptake probably results in enhanced renal elimination of polar mycophenolic acid, which reduces the risk of suffering from mycophenolate mofetil-induced ADR \[[@B6]\].

In addition to pharmacokinetics, OATP-mediated drug interactions can also have an important impact in toxicokinetics. Thus, phalloidin causes severe liver damage characterized by marked cholestasis, which is due in part to irreversible polymerization of actin filaments. Hepatocyte uptake of phalloidin is carried out mainly by OATP1B1. This process can be inhibited by compounds, such as BALU-1, a nontoxic bile acid derivative able to reduce the uptake of the toxin without impairing endogenous bile acid uptake by the major carrier accounting for this process, that is, the sodium-taurocholate cotransporting polypeptide (NTCP, gene symbol *SLC10A1*) \[[@B40]\]. In a rat model of phalloidin-induced hepatotoxicity, BALU-1 was able to protect against liver injury, due in part to the inhibition of phalloidin liver uptake and an enhancement in the biliary secretion of the toxin \[[@B41]\].

2.2. RFC Family {#sec2.2}
---------------

Folate is a member of vitamin B group and is required for the transfer of one carbon unit during nucleic acid synthesis and for amino acid metabolism. Under physiological conditions folic acid is taken up by the proton-coupled folate transporter (PCFT, gene symbol *SLC46A1*) and the reduced folate carrier (RFC, gene symbol *SLC19A1*) \[[@B42]\]. The latter, which is expressed in liver cells, is also the gate of entrance in the cell of antifolate agents, such as methotrexate \[[@B43]\]. Genetic variants in this gene have been associated to the lack of efficiency of methotrexate in several types of tumours \[[@B44], [@B45]\].

2.3. OAT Family {#sec2.3}
---------------

Organic anion transporters (OAT) are believed to behave as anion exchangers. They are able to transport many different drugs \[[@B46]\]. The preferred substrates are anionic compounds with two carboxylate groups. The first member of the family identified was OAT1 (gene symbol *SLC22A6*), which is mainly expressed in kidney. In human liver although several isoforms have been detected OAT2 (*SLC22A7*) is largely the major one \[[@B11], [@B47]\]. Several classes of drugs interact with human OATs \[[@B48]\]. These include antiviral drugs, ACE inhibitors, angiotensin II receptor antagonists, diuretics, HMG-CoA reductase inhibitors, *β*-lactam antibiotics, uricosuric drugs, antitumour drugs, such as methotrexate \[[@B47]\], 5-fluorouracil and paclitaxel \[[@B49]\], and oral selective estrogen receptor modulators, such as raloxifene \[[@B50]\], which has estrogenic actions on bone and antiestrogenic effects on uterus and breast. This accounts for its use in the prevention of osteoporosis in postmenopausal women and as part of adjuvant chemotherapy in breast cancer treatment. Identified potential substrates of OAT2 with pharmacological interest are listed in [Table 2](#tab2){ref-type="table"}.

2.4. OCT/OCTN Family {#sec2.4}
--------------------

Although belonging to the same family of genes, that is, *SLC22A*, the substrates and mechanisms of transport of organic cations transporters (OCT) are different to these of OATs. Thus, OCTs are sodium-independent electrogenic carriers able to transport small organic cations (type I), such as tetraethylammonium \[[@B51]\]. The predicted membrane topology of these transporters consists of 12 transmembrane domains with intracellular amino and carboxyl termini \[[@B52]\]. Three members of this family have been described in humans, OCT1, which is primarily expressed in liver and to a lesser extent in other organs, OCT2 and OCT3, also expressed in liver (*SLC22A1, SLC22A2,* and *SLC22A3*, resp.). The high abundance of OCT1 at the sinusoidal membrane of hepatocytes accounts for the importance of this carrier in the handling of cationic drugs by the liver ([Table 2](#tab2){ref-type="table"}). An important example among these drugs is metformin, a biguanide developed from galegine, a guanidine derivative found in *Galega officinalis*, which is widely used for the treatment of type 2 diabetes mellitus. The oral absorption, hepatic uptake, and renal excretion of metformin are mainly mediated by OCT isoforms. Thus, variability in the expression of OCT1 and OCT3 in liver, and hence presumably in the liver capability to take up metformin, has been suggested to play an important role in the interindividual differences found in the clinical efficacy of this drug \[[@B53]\]. Interestingly, an intron variant (G \> A, SNP rs2289669) of the multidrug and toxin extrusion transporter-1 (MATE1, gene symbol *SLC47A1*), mainly expressed in the kidney, but also at the canalicular membrane of hepatocytes \[[@B54]\] ([Figure 2](#fig2){ref-type="fig"}), has also been associated with a small increase in the antihyperglycemic effect of metformin in patients carrying this genetic variant \[[@B53]\].

Members of the family of carnitine/organic cation transporter (OCTN) are able to transport cations with high molecular weight (type II cations) and carnitine in a sodium-dependent and -independent manner. The transporter of carnitine and organic cations OCT6 (*SLC22A16*) also belongs to this group of carriers. The member of this family of transporters most abundantly expressed in liver cells is OCTN1, which behaves as an organic cation uniporter or H^+^/organic cation antiporter able to translocate its substrates in both directions. In addition to its presence at the plasma membrane, OCTN1 has been also localized in mitochondria \[[@B55]\], which may have important physiological and pharmacological implications.

Owing to the fact that many of the novel strategies to treat both hepatocellular carcinoma and cholangiocarcinoma include the use of tyrosine kinase inhibitors and many of them are cationic compounds \[[@B56]\], transporters able to transport these compounds are attracting much attention in modern pharmacology of liver cancer. There is already available information regarding the importance of the OCT1-tyrosine kinase inhibitors tandem in tumours affecting extrahepatic tissues. Thus, expression levels of OCT1 have been associated to the response of patients suffering from chronic myeloid leukemia to imatinib, which is taken up by this carrier \[[@B57]\]. Moreover, induction of the expression of OCT1 in lymphoma cells results in enhanced sensitivity to irinotecan and paclitaxel \[[@B58]\].

2.5. CNT and ENT Families {#sec2.5}
-------------------------

Owing to the key role of nucleosides as precursors for nucleotides required in DNA and RNA synthesis, their physiological and pharmacological interest is evident. Nucleosides are taken up by all cells using either sodium-dependent concentrative nucleoside transporters (CNT; gene symbol *SLC28A*) and/or facilitated carriers of the equilibrative nucleoside transporters family (ENT; gene symbol *SLC29A*). Members of both families are able to transport natural nucleosides and many of their derivatives ([Table 3](#tab3){ref-type="table"}). In human liver major CNT isoform is CNT2 (*SLC28A2*), followed by CNT3 (*SLC28A3*) and CNT1 (*SLC28A1*). These have a predicted topology consisting of 13 transmembrane domains with cytoplasmic amino termini and extracellular carboxyl termini \[[@B59], [@B60]\]. In contrast to CNTs, ENTs are low-affinity equilibrative carriers able to transport their substrates down concentration gradients because nucleosides are intracellularly biotransformed into nucleotides. ENTs consists of 11 transmembrane domains with intracellular amino termini and extracellular carboxyl termini \[[@B61], [@B62]\]. In human liver three isoforms are expressed in the following order of abundance: ENT1 (*SLC29A1*) \> ENT3 (*SLC29A3*) \> ENT2 (*SLC29A2*).

Since nucleotides are essential for cell proliferation, many nucleoside derivatives with antiviral and antitumour activity have been synthesized to interfere with the normal use of these compounds by viruses and cancer cells, respectively. Thus, analogues of purine bases such as 6-mercaptopurine and 6-thioguanine, and of pyrimidine bases, such as 5-fluorouracil and gemcitabine constitute an important group of antitumour drugs that require plasma membrane carriers to reach their intracellular molecular targets. Although some of these drugs can be taken up by OATs \[[@B49], [@B63]\], the main route for this process is through CNTs and/or ENTs. Thus, nucleoside transporters, in particular hENT1, seem to play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer including cholangiocarcinoma \[[@B64]\].

Treatment for hepatitis C virus infection currently consists of pegylated interferon and ribavirin, a nucleoside analogue, which is primarily taken up by ENT1. It has been suggested that reduced expression of this transporter may be involved in the acquired resistance to the treatment of hepatitis C with the drug \[[@B65]\]. Interestingly, infection of liver cells with hepatitis C viruses markedly affects vectorial transport processes typical of healthy hepatocytes \[[@B66]\].

2.6. PEPT Family {#sec2.6}
----------------

The family of peptide transporters (PEPT) includes two members, PEPT1 (*SLC15A1*) and PEPT2 (*SLC15A2*); both are highly expressed in liver. Topologically, they are predicted to have 12 transmembrane domains with both termini (amino and carboxyl) located intracellularly \[[@B67], [@B68]\]. These carriers are able to transport a broad range of substrates, which includes di- and tripeptides but not single amino acids or tetrapeptides ([Table 3](#tab3){ref-type="table"}). The transport process is driven by the inward translocation of protons, which results in an electrogenic balance of charge. The pharmacological importance of PEPTs is based on the fact that several *β*-lactam antibiotics, such as cephalosporines (cefadroxil, cefixime and ceftibuden) and penicillins (amoxicillin and ampicillin), the porphyrin precursor 5-aminolevulinic acid, and several anticancer drugs, such as bestatin, are among the substrates that can be taken up by these transporters \[[@B11]\].

2.7. CTR Family {#sec2.7}
---------------

SLC31 family members, together with the Cu-ATPases, are involved in the cellular copper homeostasis. The CTR1 transporter (gene symbol *SLC31A1*) is located at the plasma membrane of many cells, including hepatocytes. This carrier is able to take up monovalent copper by an energy-independent mechanism \[[@B69]\]. In contrast, CTR2 (gene symbol *SLC31A2*) appears to be a vacuolar/vesicular transporter \[[@B70]\]. Functional copper transporters appear to be trimeric with each subunit having three transmembrane regions and an extracellular N-terminus. CTR1 has been suggested to be involved in the transport of cisplatin-related drugs \[[@B71]\]. Indeed, reduction in the expression of this transporter has been described among the phenotypic changes occurring during development of cisplatin chemoresistance in colon cancer cells \[[@B72]\]. CTR2 has also been associated with chemoresistance to cisplatin. Thus, knockdown of CTR2 markedly increases the tumour accumulation of cisplatin and greatly enhances its therapeutic efficacy \[[@B73]\]. The exact mechanism is not known, but recent evidence suggests that CTR2 regulates the transport of cisplatin in part through control of the rate of macropinocytosis via activation of Rac1 and Cdc42 \[[@B73]\].

3. Drug Targeting {#sec3}
=================

Owing to the relative or marked selectivity of the expression at the basolateral and apical membranes of hepatocytes and cholangiocytes of carrier proteins involved in the transport of endobiotic and xenobiotic compounds, including many drugs, an important role of these transporters in the development of targeted therapies has been suggested \[[@B74]\]. The usefulness of this approach varies (i) from the possibility of using these transporters in the targeting of drug delivery systems, which can be useful either to direct anticancer drugs towards tumours located in the hepatobiliary system or toward healthy hepatocytes in order to induce or inhibit a metabolic process; (ii) to facilitate the hepatobiliary excretion once the drug has been released from the site of regional administration, for instance, during intraarterial chemoembolization of tumours. This justifies the growing interest in developing novel derivatives of cholephilic organic anions, such as bile acids, with maintained pharmacological effect characteristic of the active agent but with enhanced hepatotropism. These novel targeted pharmacological tools may be useful in the treatment of many different liver diseases, such as in anticancer chemotherapy \[[@B56]\].

The interest of using bile acids to these aims is based on the following characteristics: versatile derivatization possibilities, rigid steroidal backbone, enantiomeric purity, availability, and the low cost of natural bile acids for use in chemical reactions. Thus, bile acids are versatile building blocks to which many different substances can be attached at different positions of the steroidal skeleton or on the side chain via different chemical bonds, which can be further varied by linkers with different structures, lengths, stereochemistries, polarities, and/or functional groups. This pharmacological approach has been investigated for the targeting of very different types of drugs \[[@B75]--[@B79]\].

From the pharmacological point of view, an interesting question regarding drug design is to know the predicted topology of the interaction between the carrier and its substrates because this determines the choice of the site in the Trojan-Horse molecule to be used for its conjugation with the active agent. In the case of bile acids the possibilities for conjugating a drug include hydroxyl groups, in particular the one located at the 3*α*-position, and the carboxyl group on the side chain. The decision will depend on the expected advantages of the resulting drug, that is, enhanced intestinal absorption, improved liver vectoriality, and so forth.

Transporters of the SLC10A family, such as NTCP in hepatocytes and the apical sodium-dependent bile acid transporter (ASBT, *SLC10A2*) in cells of the intestinal epithelium and cholangiocytes, which are highly efficient in transporting bile acids, have been reported to interact with the region of these molecules that contains its side chain \[[@B80]\]. To use these transporters as uptake gates in a given drug targeting strategy, the bile acid side chain must be maintained in its natural configuration, using other groups, such as the 3*α*-hydroxyl one to bind the active agent. In contrast, derivatives obtained by coupling an active agent to the bile acid side chain are taken up by typically hepatic members of human OATP family \[[@B19]\]. Both strategies have been used to target toward liver tumours either organic \[[@B81], [@B82]\] or inorganic \[[@B83]--[@B87]\] moieties. The latter is particularly interesting because of the small size of the resulting molecule, which would increase the probability of preserving both substrate properties in regards to bile acid transporters and reactivity versus DNA, and hence the antiproliferative effect of these metals, in particular platinum(II) such as in cisplatin \[[@B88]\]. Cytostatic bile acid derivatives, such as BAMETs, are a good example of the versatility of targeted drugs because, although they were first synthesized to enhance their water miscibility \[[@B89]\], this family of compounds has proven to be excellent to target cytostatic agents toward tumours located in tissues of the enterohepatic circuit \[[@B74]\]. Moreover, they have the beneficial characteristic of being efficiently taken up by the liver and eliminated into bile. This reduces the amount of drug that escaping from the tumour, might reach the general circulation during regional therapy \[[@B90], [@B91]\].

4. Export Pumps {#sec4}
===============

The amount of drug that reaches its intracellular targets, accounted for by the balance between uptake and export, determines its therapeutic effectiveness. The main proteins involved in the reduction of the intracellular concentration of drugs are pumps, which have in common their ability to transport their substrates against a concentration gradient; that is, they are primary active transporters able to directly utilize energy from ATP hydrolysis. The majority, but not all, of these pumps belong to the superfamily of ABC proteins. The expression of these proteins in epithelial barriers and as part of excretory mechanisms, such as the hepatobiliary system, greatly affects liver and other territories availability of many drugs \[[@B92]\]. Regarding cancer chemotherapy, these pumps constitute one of the major problems accounting for the lack of response to antitumour drugs \[[@B4]\].

Considering the ability to reduce drug content in liver cells the most interesting members of the superfamily of ABC proteins include four pumps located at the canalicular membrane of hepatocytes: P-glycoprotein or multidrug resistance protein (MDR1, gene symbol *ABCB1*), MRP2, BSEP, and breast cancer resistance protein (BCRP, gene symbol *ABCG2*). In addition, under certain circumstances, such as chemical stress, the expression of basolateral pumps, such as MRP1, MRP3, and MRP4 ([Figure 2](#fig2){ref-type="fig"}), is enhanced by a mechanism that involves a retrocontrol loop between the mitochondrial and nuclear genomes \[[@B93]\].

ABCB family includes the prototypic ABC protein, that is, MDR1, which is expressed in many epithelial and nonepithelial tissues, where it plays an important role in the export of a large variety of compounds, including many drugs ([Table 4](#tab4){ref-type="table"}) \[[@B11], [@B94]\]. This glycoprotein consists of two halves of 6 transmembrane domains and a cytoplasmic nucleotide binding domain (NBD) each.

In the liver this pump is important regarding three functions: (i) elimination of toxic compounds that may induce liver, and other organs, damage, (ii) elimination of drugs, which would greatly affect their bioavailability, and (iii) chemoresistance, when MDR1 is expressed in liver tumours \[[@B95]--[@B98]\].

Another member of the ABCB family is BSEP, which is believed to be the major mechanism accounting for the generation of the osmotic gradient of bile acids that determines the formation of an important fraction of bile flow \[[@B99]\]. Owing to the marked substrate specificity of this pump and its almost exclusive localization at the canalicular membrane of hepatocytes, regarding the ability to secrete drugs into bile its pharmacological relevance is low. However, due to its pivotal role in bile formation, its inhibition by several compounds known to be competitive inhibitors of BSEP may account for acquired cholestasis occurring under certain circumstances \[[@B100]\]. For some compounds, such as estrogens and progesterone derivatives the ability to inhibit BSEP from the canalicular lumen once has been secreted, presumably through other canalicular pumps, has been reported \[[@B101], [@B102]\].

Several members of the ABCC family are expressed in the liver. To understand their role in pharmacology it is important to distinguish between two groups of ABCC pumps. On one hand there are MRPs poorly expressed under physiological circumstances and located at the basolateral membrane, such as MRP1, MRP3-9 \[[@B11]\], whose role in drug handling is probably minor, but this is not well understood. On the other hand, MRP2 is highly expressed at the canalicular membrane, where this pump plays a crucial role in detoxification, mainly exporting compounds that have undergone phase II biotransformation, that is, conjugation with glutathione, glucuronate, sulphate, or taurine ([Table 4](#tab4){ref-type="table"}). Recently, the presence of MRP2 at the nuclear envelop of hepatocytes together with conjugating enzymes has led to suggest that this may constitute a barrier to protect the nuclear content from genotoxic compounds \[[@B103]\].

However, the situation is very different in cancer chemotherapy, because liver tumour cells can overexpress one or several members of the ABCC family, which may enhance their ability to eliminate a large variety of drugs and hence becoming resistant to the pharmacological treatment \[[@B104]\]. Thus, the expression of MRP2 has been associated with a reduction in the efficacy of cisplatin-based chemotherapy of patients with hepatocellular carcinoma \[[@B105], [@B106]\]. Moreover, there is a marked overlapping in substrate specificity of MRP2 with other members of this family, such as MRP1 and MRP3. These have been shown to induce resistance to *Vinca*alkaloids, anthracyclines, camptothecins, chlorambucil, cisplatin, cyclophosphamide, irinotecan, methotrexate, paclitaxel, podophyllotoxins, and tamoxifen \[[@B107], [@B108]\].

In contrast to ABCB and ABCC families, whose members have two halves of six transmembrane domains with two NBD, ABCG members are half-transporters with a predicted topology of 6 transmembrane domains and a single NBD. These must form homo- or heterodimers to become functional pumps. BCRP is expressed in many territories including the canalicular membrane of hepatocytes \[[@B109]\]. This pump is involved in the secretion into bile of a large number of compounds, which include bile acids, although this physiological role has been recently evaluated as more important in placenta, whereas in liver this is probably minor as compared to that of BSEP \[[@B110]\].

Regarding substrate specificity, BCRP shares with MDR1 a marked but not complete overlapping ([Table 4](#tab4){ref-type="table"}). Among the drugs transported by BCRP are important agents used in cancer chemotherapy, such as mitoxantrone, topotecan and methotrexate \[[@B111]\], nucleoside analogues, such as cladribine and clofarabine \[[@B112]\], 5-fluorouracil \[[@B113]\], oxaliplatin \[[@B114]\], and cisplatin \[[@B115]\], which account for the important role of this pump in the development of chemoresistance by many haematological and solid tumours, including liver tumours \[[@B116]\]. At this respect, we have recently reported that BCRP may play a role in chemoresistance induced by exposure of tumour cells to cisplatin \[[@B115]\]. The overexpression of BCRP may also play a role in the development of refractoriness to the pharmacological treatment of liver cancer in paediatric patients \[[@B117]\]. In addition to anticancer agents, BCRP is also capable of transporting nonchemotherapy drugs, including nitrofurantoin, prazosin, glyburide, and 2-amino-1-methyl-6-phenylimidazo \[4,5-b\]pyridine (PhIP) \[[@B111]\].

Beside ABC proteins, there are other active primary transporters able to export drugs that have been included among the mechanisms of chemoresistance type 1b (MOC-1b) \[[@B4]\]. These include P-type ATPases, such as the Menkes (ATP7A) and Wilson (ATP7B) proteins. These are copper transporters able to transport cisplatin derivatives \[[@B118]\]. Wilson protein is expressed at the canalicular membrane of hepatocytes where it plays an important role in copper homeostasis but may also be involved in the elimination of metal-containing drugs by normal liver as well as from liver-derived tumours \[[@B119]\], where this protein has been found highly expressed \[[@B120]\].

5. Chemosensitization {#sec5}
=====================

Since the activity of ABC proteins may reduce the efficacy of drugs when maintained levels of the active agent, either in general circulation or in tumour tissue, are required, an intense effort is being carried out to develop novel-specific reversing agents for these pumps, which can be included in the general concept of chemosensitizers \[[@B56], [@B121]\].

The ongoing search for compounds that act directly on the ABC transporter proteins to block their activity has led to three generations of drugs. Among the compounds used in the first generation of chemosensitizers are the calcium channel blocker verapamil and the immunomodulator cyclosporine A, which are able to inhibit MDR1 but are poor substrates of this pump. Both were able to efficiently resensitize *in vitro* MDR1-mediated drug resistant cancer cells. Although these compounds entered clinical trials, they failed to be useful for cancer patients due to the high dose required and the adverse effects of the combined treatment with verapamil \[[@B122]--[@B124]\] or cyclosporine A \[[@B125], [@B126]\]. In an attempt to enhance beneficial properties and reduce adverse effects a second generation of MDR1 modulators was developed. Among them the most promising compound was a cyclosporine A analogue, SDZ PSC833 or valspodar. This drug is 10- to 20-fold stronger in inhibiting MDR1 activity, but, unfortunately, side effects are also more serious. Clinical trials revealed that valspodar administration resulted in overexposing the patients to increased serum concentrations of cytotoxic drug \[[@B127]--[@B129]\]. Some of the third generation of chemosensitizers are LY335979 (zosuquidar), GF12918 (elacridar), and CBT-1 and XR9576 (tariquidar) \[[@B130]\]. These are highly effective even at nanomolar concentrations and have promising properties compared to those obtained in earlier generations. Interestingly, these ABC modulators are less toxic and they do not affect the pharmacokinetics of anticancer drugs \[[@B130]\]. Part of the differential advantages of these drugs is their specificity. For instance, zosuquidar is able to inhibit MDR1 with high efficacy (Ki approximately 60 nM) but has no inhibitory effect on MRPs or BCRP \[[@B131]\].

Chemosensitization can be also achieved by increasing the amount of drug taken up by tumour cells. In addition to the above commented possibility of reaching this aim by drug targeting, there is the option of restoring or enhance the expression or the function of carriers naturally involved in this process. The copper transporter CTR1, a major influx transporter for platinum drugs, can be used as an example to illustrate these possibilities. Thus, in a mouse model of human cervical cancer, the combined treatment of cisplatin with a copper chelator increases the availability of CTR1 to take up cisplatin, which results in enhanced cisplatin-DNA adduct levels in cancerous but not in normal tissues, impaired angiogenesis, and improved therapeutic efficacy. In addition, cisplatin is known to reduce CTR1 expression by stimulation of proteasomal degradation of this carrier, which limits the capability of tumour cells to take up this drug. Treatment with bortezomib, a proteasomal inhibitor, blocks cisplatin-induced CTR1 degradation and hence increases the abundance of transporter proteins at the plasma membrane of ovarian cancer cells as well as their capability to take up cisplatin, which results in enhanced activation of apoptosis \[[@B132]\].

6. Conclusions and Perspectives {#sec6}
===============================

Among the challenges of modern hepatic pharmacology are the understanding of the role of plasma membrane transporters in drug pharmacokinetics together with the influence of genetic and environmental factors in the expression and function of these transporters. This is important because drug transporters are involved in adverse effects due to drug interactions, which limit the clinical usefulness of some pharmacological combinations and affect the acceptance of novel drugs by regulatory agencies. Advances in this field will permit to develop new generation of drugs with lower risk of drug interactions but enhanced beneficial properties regarding increased hepatotropism and/or the ability to overcome transporter-mediated chemoresistance.

Another factor that is gaining interest because it may influence the role of transporters in the final effect of any pharmacological treatment is the existence of circadian rhythms in organs involved in drug disposition. Thus, mouse orthologues of OCT1 and OATPs expressed in liver (Oatp1a1, Oatp1a4, and Oatp1b2) have a maximal expression at approximately the second half of light day (2:00 p.m.), whereas no circadian fluctuations in the liver expression of Ntcp and Ent1 have been reported \[[@B133]\]. Regarding canalicular pumps, mRNA levels of the murine orthologues of BSEP, MRP2, and BCRP show mild or none circadian fluctuations, whereas those of rodent orthologue of MDR1 have a peak at 10:00 p.m. \[[@B133]\]. Whether similar rhythms also exist in humans is poorly understood, but it is known that disturbed circadian regulation, for instance due to jet-lag, shift work, and dysfunction of core clock genes, leads to changed periods of activity, sleep disorders, disturbed glucose homeostasis, enhanced risk of developing breast or colon cancer, and metabolic syndrome. Similarly, impairment of the physiological clock may also influence the circadian rhythm of the liver affecting good timing of drug administration, which can account for reduced success of the pharmacological treatment \[[@B134]\].
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![Export pumps involved in drug export across the basolateral and canalicular membrane of hepatocytes.](SCIENTIFICA2012-428139.002){#fig2}

###### 

Identified potential substrates of hepatic forms of OATPs with pharmacological interest.

                                   OATP1B1                          OATP1B3                          OATP1A2
  -------------------------------- -------------------------------- -------------------------------- ---------
  Substrates                       Benzylpenicillin                                                   
  Bile acid derivatives (BAMETS)   Bile acid derivatives (BAMETS)   Bile acid derivatives (BAMETS)   
  Bilirubin and its conjugates     Bilirubin conjugates                                              
  Bosentan                         Bosentan                                                          
  BQ-123                           BQ-123                           BQ-123                           
  Bromosulfophthalein              Bromosulfophthalein              Bromosulfophthalein              
  Caspofungin                                                                                        
  Cerivastatin                     Cholecystokinin-8                                                 
  Cholic acid                                                       Cholic acid                      
  DHEA sulphate                    DHEA sulphate                    DHEA sulphate                    
                                   Deltorphin II                    Deltophorin II                   
                                   Digoxin                                                           
  DPDPE                            DPDPE                            DPDPE                            
                                   Docetaxel                                                         
  Enalapril                        Enalapril                                                         
  Estradiol 17*β*-glucuronide      Estradiol 17*β*-glucuronide                                       
  Estrone-3-sulphate                                                Estrone-3-sulphate               
                                   Fexofenadine                     Fexofenadine                     
  Flavopiridol                     Flavopiridol                                                      
  Fluvastatin                      Fluvastatin                                                       
  Glycocholate                     Glycocholate                     Glycocholate                     
  Irinotecan and SN-38             Irinotecan and SN-38                                              
                                                                    Imatinib                         
                                                                    Levofloxacin                     
  Leukotriene C4                   Leukotriene C4                                                    
  Methotrexate                     Methotrexate                     Methotrexate                     
  Microcystin-LR                   Microcystin-LR                   Microcystin-LR                   
  Olmesartan                       Olmesartan                                                        
                                   Ouabain                          Ouabain                          
  Paclitaxel                       Paclitaxel                                                        
  Phalloidin                       Phalloidin                                                        
                                                                    D-Penicillamine                  
  Pravastatin                                                       Pravastatin                      
  Prostaglandin E2                                                  Prostaglandin E2                 
  Rifampicin                       Rifampicin                                                        
  Rosuvastatin                     Rosuvastatin                     Rosuvastatin                     
                                                                    Saquinavir                       
  Taurocholate                     Taurocholate                     Taurocholate                     
                                   Telmisartan                                                       
  Thromboxane B2                                                                                     
  Thyroxine                        Thyroxine                        Thyroxine                        
  Triiodothyronine                 Triiodothyronine                 Triiodothyronine                 
  Troglitazone sulphate                                                                              
  Valsartan                        Valsartan                                                         

###### 

Identified potential substrates of hepatic forms of OATs, OCTs, and OCTNs with pharmacological interest.

                        OAT2                          OCT1                 OCTN1
  --------------------- ----------------------------- -------------------- -------------
  Substrates            *p*-Aminohippurate            Acetylcholine        L-Carnitine
  Acetylsalicylate      Acyclovir                     Ergothioneine        
  Allopurinol           Cimetidine                    Pyrilamine           
  Bumetanide            Choline                       Quinidine            
  Cyclic AMP            Dopamine                      Quinine              
  DHEA sulphate         Epinephrine                   Tetraethylammonium   
  Estrone-3-sulphate    Famotidine                    Verapamil            
  5-Fluorouracil        Ganciclovir                                        
  Glutarate             Histamine                                          
  *α*-Ketoglutarate     Imatinib                                           
  Methotrexate          Lamivudine                                         
  Ochratoxin A          Metformin                                          
  Paclitaxel            N-Methylnicotinamide                               
  Prostaglandin E2      1-Methyl-4-phenylpyridinium                        
  Prostaglandin F2*α*   Norepinephrine                                     
  Raloxifene            Quinine                                            
  Salicylate            Ranitidine                                         
  Tetracycline          Serotonin                                          
  Valproic acid         Spermidine                                         
  Zidovudine            Spermine                                           
                        Tetraethylammonium                                 
                        Zalcitabine                                        

###### 

Identified potential substrates of hepatic forms of CNTs, ENTs, and PEPTs with pharmacological interest.

                       CNT1-3         ENT1-3            PEPT1-2
  -------------------- -------------- ----------------- -----------------------
  Substrates                          Adenine           5-Aminolevulinic acid
                                      Amoxicillin       
                                      Ampicillin        
  Adenosine            Adenosine      Bestatin          
  Benzamide riboside                  Cefadroxil        
  Cladribine           Cladribine     Cefixime          
  Clofarabin           Clofarabine    Ceftibuten        
  Cytarabine                          Cephalexin        
  Cytidine             Cytidine       Cephradine        
  Didanosine                          Glycylsarcosine   
  Fialuridine          Fialuridine    L-Kyotorphin      
  Fludarabine          Fludarabine                      
  5-Fluorouridine                                       
  Formycin                                              
  Gemcitabine          Gemcitabine                      
                       Guanine                          
  Guanosine            Guanosine                        
                       Hypoxanthine                     
  6-Mercaptopurine                                      
  Inosine              Inosine                          
  Ribavirin            Ribavirin                        
  Stavudine                                             
  6-Thioguanine                                         
  Thymidine            Thymidine                        
  Tiazofurin           Tiazofurin                       
  Uridine              Uridine                          
  Zalcitabine                                           
  Zebularine           Zebularine                       
  Zidovudine           Zidovudine                       

###### 

Identified potential substrates of canalicular forms of ABC proteins with pharmacological interest.

                        MDR1                                MRP2                          BCRP
  --------------------- ----------------------------------- ----------------------------- ----------
  Substrates            Actinomycin D                       Acetaminophen-glucuronide     Abacavir
  Amitriptyline         Acetaminophen-sulphate              Aflatoxin B                   
  Amsacrine             *p*-Aminohippurate                  Albendazole sulfoxide         
  Bisantrene            Arsenic-glutathione                 Bile acids                    
  Camptothecins         Bilirubin-glucuronide               Ciprofloxacin                 
  Cerivastatin          BQ-123                              Coumestrol                    
  Colchicine            Diclofenac-glucuronide              Daidzein                      
  Cyclosporine A        S-(2,4-Dinitrophenyl)-glutathione   Dantrolene                    
  Daunorubicin          Estradiol-17*β*-glucuronide         DHEA sulphate                 
  Digoxin               Ethacrynic acid-glutathione         Dipyridamole                  
  Diltiazem             Ethinylestradiol glucuronide        Edaravone sulphate            
  Docetaxel             4-Hydroxynonenal-glutathione        Enrofloxacin                  
  Domperidone           Indinavir                           Erlotinib                     
  Doxorubicin           Leukotriene C4                      Estradiol-17*β*-glucuronide   
  Erlotinib             Methotrexate                        Estrone-3-sulphate            
  Erythromycin          Morphine-3-glucuronide              Etoposide                     
  Etoposide             Ochratoxin A                        Furosemide                    
  Fexofenadine          Oxidized/reduced glutathione        Gefitinib                     
  Imatinib              PhIP                                Genistein                     
  Indinavir             Ritonavir                           Glyburide                     
  Ivermectin            Saquinavir                          Grepafloxacin                 
  Lapatinib             Sulfotaurolithocholic acid          Hematoporphyrin               
  Loperamide            Taurocholic acid                    Hoechst                       
  Losartan              Taurolithocholate sulphate          Hydrochlorothiazide           
  Lovastatin            Vinblastine                         Imatinib                      
  Methotrexate          Vincristine                         Lamivudine                    
  Mitoxantrone                                              Lapatinib                     
  Nelfinavir                                                Methotrexate                  
  Ondansetron                                               Mitoxantrone                  
  Oseltamivir                                               Nitrofurantoin                
  Paclitaxel                                                Norfloxacin                   
  Phenytoin                                                 Ofloxacin                     
  Prazosin                                                  Oxfendazole                   
  Quinidine                                                 Pheophorbide A                
  Ritonavir                                                 PhIP                          
  Saquinavir                                                Prazosin                      
  Sparfloxacin                                              Resveratrol 3-sulphate        
  Tamoxifen                                                 Resveratrol di-sulphate       
  Terfenadine                                               Riboflavin                    
  Tetracycline                                              Rosuvastatin                  
  (99m)Tc-Tetrofosmin                                       Triamterene                   
  Topotecan                                                 Ulifloxacin                   
  Vecuronium                                                Zidovudine                    
  Verapamil                                                                               
  Vinblastine                                                                             
  Vincristine                                                                             
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